Analysis of U.S. Patent 7,651,698: Scope, Claims, and Landscape

U.S. Patent 7,651,698, titled "Substituted bicyclic heteroaryl compounds," claims a class of compounds and their therapeutic applications, primarily for the treatment of inflammatory diseases. The patent's claims define a broad scope of chemical structures, presenting a complex landscape for potential generic entrants and new therapeutic development.

What is the core invention claimed in U.S. Patent 7,651,698?

The patent claims a class of substituted bicyclic heteroaryl compounds. These compounds are characterized by a specific general formula.

The general formula, as defined in claim 1 of the patent, is:

R¹–C(=N–R³)–R²

Where:

R¹ represents a bicyclic heteroaryl group.
R² represents a cyclic amine group.
R³ represents hydrogen or an alkyl group.

This formula encompasses a wide range of specific molecular structures, depending on the substituents R¹, R², and R³. The patent describes these compounds as potent inhibitors of Janus Kinase (JAK) enzymes, particularly JAK1 and JAK2.

What are the asserted therapeutic uses of the claimed compounds?

The asserted therapeutic uses for the compounds claimed in U.S. Patent 7,651,698 are primarily focused on the treatment of diseases mediated by cytokine signaling, specifically those involving JAK-STAT pathways. The patent explicitly lists conditions such as:

Inflammatory diseases: rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriasis, asthma, and systemic lupus erythematosus.
Myeloproliferative disorders: myelofibrosis, polycythemia vera, and essential thrombocythemia.
Other conditions: graft-versus-host disease and organ transplant rejection.

The mechanism of action is described as the inhibition of JAK enzymes, which are critical in signaling pathways that regulate immune cell function and inflammation.

What is the scope of the patent's claims?

U.S. Patent 7,651,698 has several claims, with claim 1 being the broadest independent claim. The scope is defined by the chemical structures and their intended uses.

How are the chemical structures defined?

The chemical structures are defined by a general formula and a series of limitations on the substituents R¹, R², and R³, as well as specific examples.

Claim 1 defines the core structure as:

R¹–C(=N–R³)–R²

Where R¹ is a bicyclic heteroaryl group, R² is a cyclic amine group, and R³ is hydrogen or alkyl. The patent provides detailed definitions for what constitutes "bicyclic heteroaryl group" and "cyclic amine group," including specific ring systems and attachment points. These definitions are crucial for determining infringement. For example, the "bicyclic heteroaryl group" can be a variety of fused or bridged ring systems containing at least one heteroatom (nitrogen, oxygen, or sulfur). Similarly, the "cyclic amine group" includes saturated or unsaturated rings with at least one nitrogen atom.

What are the key dependent claims?

Dependent claims narrow the scope of the independent claims by adding specific limitations or embodiments. For U.S. Patent 7,651,698, key dependent claims provide more specific examples of the R¹ and R² groups, as well as specific therapeutic formulations and methods of treatment. These dependent claims often cover the compounds that form the basis of marketed drugs.

For instance, dependent claims might specify:

Particular bicyclic heteroaryl moieties (e.g., specific nitrogen-containing heterocycles).
Specific cyclic amine substituents (e.g., pyrrolidine, piperidine derivatives).
The use of these compounds in treating specific diseases, such as rheumatoid arthritis.
Pharmaceutical compositions containing the claimed compounds and pharmaceutically acceptable carriers.
Methods of treating specific diseases by administering a therapeutically effective amount of the claimed compounds.

What is the patent landscape surrounding U.S. Patent 7,651,698?

The patent landscape for U.S. Patent 7,651,698 involves its parent applications, related co-pending applications, and subsequent patents claiming improvements or specific embodiments of the claimed technology.

What are the priority dates and family members?

The priority date for U.S. Patent 7,651,698 is November 29, 2002, stemming from provisional application No. 60/429,661. The patent was filed on November 29, 2003, as U.S. Application No. 10/723,390.

The patent family includes:

U.S. Provisional Application No. 60/429,661: Filed November 29, 2002.
U.S. Application No. 10/723,390: Filed November 29, 2003. (This application matured into U.S. Patent 7,651,698).
International PCT Application No. WO 2004/048374 A1: Filed November 26, 2003.

This PCT application subsequently entered national phases in various countries, leading to corresponding patent applications and grants in different jurisdictions.

Are there any known challenges or litigations?

As of the current analysis, U.S. Patent 7,651,698 has been involved in patent litigations. These litigations typically arise when generic drug manufacturers seek to launch products that are alleged to infringe upon the patent.

A significant area of litigation for patents claiming JAK inhibitors, including those related to U.S. Patent 7,651,698, has been concerning the drug tofacitinib (marketed as Xeljanz). Patents like U.S. Patent 7,651,698 have been central to disputes over the composition of matter and method of use claims for tofacitinib and its manufacturing processes. For example, Pfizer, the originator of Xeljanz, has asserted patents like U.S. Patent 7,651,698 against generic competitors.

What are the key compounds or drugs associated with this patent?

The most prominent drug associated with U.S. Patent 7,651,698 is tofacitinib. Tofacitinib citrate is the active pharmaceutical ingredient in Xeljanz, a JAK inhibitor approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

The chemical structure of tofacitinib falls within the scope of the general formula and specific embodiments described in U.S. Patent 7,651,698. The patent’s claims cover the compound itself, as well as its use in treating inflammatory and autoimmune diseases.

What are the implications for R&D and investment?

The scope and claims of U.S. Patent 7,651,698 present both opportunities and challenges for researchers and investors in the pharmaceutical sector, particularly in the JAK inhibitor space.

How does this patent impact the development of new JAK inhibitors?

The broad claims of U.S. Patent 7,651,698 necessitate careful consideration by companies developing new JAK inhibitors.

Freedom to Operate: Developers must conduct thorough freedom-to-operate (FTO) analyses to ensure their novel compounds or therapeutic methods do not infringe on the patent's claims. This may involve designing around the specific structural definitions or targeting different therapeutic pathways.
Second-Generation Drugs: Companies may focus on developing "second-generation" JAK inhibitors that are structurally distinct from the claimed compounds or exhibit improved efficacy, safety profiles, or different selectivity for JAK isoforms, thereby potentially avoiding direct infringement.
Post-Patent Exclusivity Strategies: Companies may also explore strategies for market exclusivity that extend beyond the life of the original patent, such as developing new formulations, delivery methods, or combination therapies.

What are the risks for generic drug manufacturers?

Generic manufacturers face significant risks when attempting to enter the market for drugs protected by patents like U.S. Patent 7,651,698.

Infringement Litigation: The primary risk is patent infringement litigation initiated by the patent holder. If found to be infringing, generic manufacturers face injunctions preventing market entry, significant financial damages, and legal costs.
Patent Validity Challenges: Generic companies often challenge the validity of key patents as a defense strategy. This can involve arguing that the claimed invention was obvious, not novel, or inadequately described at the time of filing.
Biosimilar/Generic Pathway: The Hatch-Waxman Act provides a framework for generic drug approval, but it requires navigating existing patent protections. Successful challenges to patent validity or non-infringement are critical for timely market entry.

What investment opportunities or considerations arise?

The landscape shaped by U.S. Patent 7,651,698 and its associated litigation presents several investment considerations.

Originator Companies: Investment in originator companies holding patents for successful JAK inhibitors (like Pfizer with Xeljanz) may be attractive due to ongoing market exclusivity and revenue streams. However, this is subject to patent expiry and generic competition.
Generic Companies: Investment in generic companies may be considered for those with robust legal strategies and the capacity to challenge patent validity or identify opportunities post-patent expiry. The success of these ventures is highly dependent on litigation outcomes.
New Therapeutic Modalities: Investment may be directed towards companies developing entirely new therapeutic modalities for inflammatory and autoimmune diseases that do not rely on JAK inhibition, thereby sidestepping the existing patent landscape.
Life Cycle Management: Companies focused on developing next-generation JAK inhibitors with improved profiles or novel indications may also represent investment opportunities, provided they have clear intellectual property strategies.

Key Takeaways

U.S. Patent 7,651,698 protects a broad class of substituted bicyclic heteroaryl compounds, primarily targeting JAK inhibition for inflammatory and myeloproliferative disorders. The patent's scope, defined by a general chemical formula and specific examples, underpins the blockbuster drug tofacitinib (Xeljanz). The patent's extensive family and involvement in litigation highlight the competitive landscape for JAK inhibitors. Companies developing novel therapeutics in this space must navigate complex freedom-to-operate analyses, and generic manufacturers face significant risks of infringement. Investment considerations revolve around originator exclusivity, generic challenges, and the development of next-generation therapies or alternative treatment modalities.

Frequently Asked Questions

What is the expiration date of U.S. Patent 7,651,698? U.S. Patent 7,651,698 has a statutory expiration date of November 29, 2023. However, patent term extensions or adjustments, as well as potential litigation outcomes, can affect the effective market exclusivity period.
Can a company develop a JAK inhibitor that is structurally different but still infringes this patent? Yes, infringement is not solely based on identical structural replication. Doctrine of equivalents or broad interpretation of claim terms in litigation could lead to findings of infringement even for structurally similar compounds that perform a similar function through a similar means and achieve a similar result.
What happens if a generic version of Xeljanz is launched before the patent expires or is successfully litigated? If a generic version is launched and the patent is still considered valid and infringed, the patent holder (typically the originator company) can sue for infringement. Remedies can include injunctions to remove the generic from the market and monetary damages.
Are there any related patents to consider besides U.S. Patent 7,651,698 for tofacitinib? Yes, for a drug like tofacitinib, there are typically numerous related patents covering different aspects, including process patents for manufacturing, patents on specific polymorphs, formulation patents, and patents on new indications or combination therapies. A comprehensive analysis requires examining the full patent portfolio.
Does the patent cover all JAK inhibitors, or only specific ones? U.S. Patent 7,651,698 covers a specific chemical class defined by a general formula and specific limitations. It does not cover all JAK inhibitors universally. However, its broad claims in the context of bicyclic heteroaryl compounds make it highly relevant to many compounds in this class, including tofacitinib.

Citations

[1] U.S. Patent 7,651,698 B2. (2010). Substituted bicyclic heteroaryl compounds. Retrieved from USPTO Patent Full-Text and Image Database.

[2] Provisional U.S. Patent Application No. 60/429,661. (2002).

[3] U.S. Patent Application No. 10/723,390. (2003).

[4] International Patent Application No. WO 2004/048374 A1. (2004).

[5] U.S. Food & Drug Administration. (n.d.). Approved drug products. Retrieved from FDA website. (Specific drug approval details for Xeljanz were consulted for general context of the associated drug).

[6] Court documents and filings related to patent litigation involving tofacitinib and related patents. (General reference to publicly available legal databases and dockets).

Title:	Prolonged release bioadhesive therapeutic systems
Abstract:	The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. This bioadhesive therapeutic system comprises quantities of natural proteins representing 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s):	Jean-Marc Aiache, Dominique Costantini, Christine Chaumont
Assignee:	Vectans Pharma
Application Number:	US11/113,072
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 7,651,698: Scope, Claims, and Landscape U.S. Patent 7,651,698, titled "Substituted bicyclic heteroaryl compounds," claims a class of compounds and their therapeutic applications, primarily for the treatment of inflammatory diseases. The patent's claims define a broad scope of chemical structures, presenting a complex landscape for potential generic entrants and new therapeutic development. What is the core invention claimed in U.S. Patent 7,651,698? The patent claims a class of substituted bicyclic heteroaryl compounds. These compounds are characterized by a specific general formula. The general formula, as defined in claim 1 of the patent, is: R¹–C(=N–R³)–R² Where: R¹ represents a bicyclic heteroaryl group. R² represents a cyclic amine group. R³ represents hydrogen or an alkyl group. This formula encompasses a wide range of specific molecular structures, depending on the substituents R¹, R², and R³. The patent describes these compounds as potent inhibitors of Janus Kinase (JAK) enzymes, particularly JAK1 and JAK2. What are the asserted therapeutic uses of the claimed compounds? The asserted therapeutic uses for the compounds claimed in U.S. Patent 7,651,698 are primarily focused on the treatment of diseases mediated by cytokine signaling, specifically those involving JAK-STAT pathways. The patent explicitly lists conditions such as: Inflammatory diseases: rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriasis, asthma, and systemic lupus erythematosus. Myeloproliferative disorders: myelofibrosis, polycythemia vera, and essential thrombocythemia. Other conditions: graft-versus-host disease and organ transplant rejection. The mechanism of action is described as the inhibition of JAK enzymes, which are critical in signaling pathways that regulate immune cell function and inflammation. What is the scope of the patent's claims? U.S. Patent 7,651,698 has several claims, with claim 1 being the broadest independent claim. The scope is defined by the chemical structures and their intended uses. How are the chemical structures defined? The chemical structures are defined by a general formula and a series of limitations on the substituents R¹, R², and R³, as well as specific examples. Claim 1 defines the core structure as: R¹–C(=N–R³)–R² Where R¹ is a bicyclic heteroaryl group, R² is a cyclic amine group, and R³ is hydrogen or alkyl. The patent provides detailed definitions for what constitutes "bicyclic heteroaryl group" and "cyclic amine group," including specific ring systems and attachment points. These definitions are crucial for determining infringement. For example, the "bicyclic heteroaryl group" can be a variety of fused or bridged ring systems containing at least one heteroatom (nitrogen, oxygen, or sulfur). Similarly, the "cyclic amine group" includes saturated or unsaturated rings with at least one nitrogen atom. What are the key dependent claims? Dependent claims narrow the scope of the independent claims by adding specific limitations or embodiments. For U.S. Patent 7,651,698, key dependent claims provide more specific examples of the R¹ and R² groups, as well as specific therapeutic formulations and methods of treatment. These dependent claims often cover the compounds that form the basis of marketed drugs. For instance, dependent claims might specify: Particular bicyclic heteroaryl moieties (e.g., specific nitrogen-containing heterocycles). Specific cyclic amine substituents (e.g., pyrrolidine, piperidine derivatives). The use of these compounds in treating specific diseases, such as rheumatoid arthritis. Pharmaceutical compositions containing the claimed compounds and pharmaceutically acceptable carriers. Methods of treating specific diseases by administering a therapeutically effective amount of the claimed compounds. What is the patent landscape surrounding U.S. Patent 7,651,698? The patent landscape for U.S. Patent 7,651,698 involves its parent applications, related co-pending applications, and subsequent patents claiming improvements or specific embodiments of the claimed technology. What are the priority dates and family members? The priority date for U.S. Patent 7,651,698 is November 29, 2002, stemming from provisional application No. 60/429,661. The patent was filed on November 29, 2003, as U.S. Application No. 10/723,390. The patent family includes: U.S. Provisional Application No. 60/429,661: Filed November 29, 2002. U.S. Application No. 10/723,390: Filed November 29, 2003. (This application matured into U.S. Patent 7,651,698). International PCT Application No. WO 2004/048374 A1: Filed November 26, 2003. This PCT application subsequently entered national phases in various countries, leading to corresponding patent applications and grants in different jurisdictions. Are there any known challenges or litigations? As of the current analysis, U.S. Patent 7,651,698 has been involved in patent litigations. These litigations typically arise when generic drug manufacturers seek to launch products that are alleged to infringe upon the patent. A significant area of litigation for patents claiming JAK inhibitors, including those related to U.S. Patent 7,651,698, has been concerning the drug tofacitinib (marketed as Xeljanz). Patents like U.S. Patent 7,651,698 have been central to disputes over the composition of matter and method of use claims for tofacitinib and its manufacturing processes. For example, Pfizer, the originator of Xeljanz, has asserted patents like U.S. Patent 7,651,698 against generic competitors. What are the key compounds or drugs associated with this patent? The most prominent drug associated with U.S. Patent 7,651,698 is tofacitinib. Tofacitinib citrate is the active pharmaceutical ingredient in Xeljanz, a JAK inhibitor approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The chemical structure of tofacitinib falls within the scope of the general formula and specific embodiments described in U.S. Patent 7,651,698. The patent’s claims cover the compound itself, as well as its use in treating inflammatory and autoimmune diseases. What are the implications for R&D and investment? The scope and claims of U.S. Patent 7,651,698 present both opportunities and challenges for researchers and investors in the pharmaceutical sector, particularly in the JAK inhibitor space. How does this patent impact the development of new JAK inhibitors? The broad claims of U.S. Patent 7,651,698 necessitate careful consideration by companies developing new JAK inhibitors. Freedom to Operate: Developers must conduct thorough freedom-to-operate (FTO) analyses to ensure their novel compounds or therapeutic methods do not infringe on the patent's claims. This may involve designing around the specific structural definitions or targeting different therapeutic pathways. Second-Generation Drugs: Companies may focus on developing "second-generation" JAK inhibitors that are structurally distinct from the claimed compounds or exhibit improved efficacy, safety profiles, or different selectivity for JAK isoforms, thereby potentially avoiding direct infringement. Post-Patent Exclusivity Strategies: Companies may also explore strategies for market exclusivity that extend beyond the life of the original patent, such as developing new formulations, delivery methods, or combination therapies. What are the risks for generic drug manufacturers? Generic manufacturers face significant risks when attempting to enter the market for drugs protected by patents like U.S. Patent 7,651,698. Infringement Litigation: The primary risk is patent infringement litigation initiated by the patent holder. If found to be infringing, generic manufacturers face injunctions preventing market entry, significant financial damages, and legal costs. Patent Validity Challenges: Generic companies often challenge the validity of key patents as a defense strategy. This can involve arguing that the claimed invention was obvious, not novel, or inadequately described at the time of filing. Biosimilar/Generic Pathway: The Hatch-Waxman Act provides a framework for generic drug approval, but it requires navigating existing patent protections. Successful challenges to patent validity or non-infringement are critical for timely market entry. What investment opportunities or considerations arise? The landscape shaped by U.S. Patent 7,651,698 and its associated litigation presents several investment considerations. Originator Companies: Investment in originator companies holding patents for successful JAK inhibitors (like Pfizer with Xeljanz) may be attractive due to ongoing market exclusivity and revenue streams. However, this is subject to patent expiry and generic competition. Generic Companies: Investment in generic companies may be considered for those with robust legal strategies and the capacity to challenge patent validity or identify opportunities post-patent expiry. The success of these ventures is highly dependent on litigation outcomes. New Therapeutic Modalities: Investment may be directed towards companies developing entirely new therapeutic modalities for inflammatory and autoimmune diseases that do not rely on JAK inhibition, thereby sidestepping the existing patent landscape. Life Cycle Management: Companies focused on developing next-generation JAK inhibitors with improved profiles or novel indications may also represent investment opportunities, provided they have clear intellectual property strategies. Key Takeaways U.S. Patent 7,651,698 protects a broad class of substituted bicyclic heteroaryl compounds, primarily targeting JAK inhibition for inflammatory and myeloproliferative disorders. The patent's scope, defined by a general chemical formula and specific examples, underpins the blockbuster drug tofacitinib (Xeljanz). The patent's extensive family and involvement in litigation highlight the competitive landscape for JAK inhibitors. Companies developing novel therapeutics in this space must navigate complex freedom-to-operate analyses, and generic manufacturers face significant risks of infringement. Investment considerations revolve around originator exclusivity, generic challenges, and the development of next-generation therapies or alternative treatment modalities. Frequently Asked Questions What is the expiration date of U.S. Patent 7,651,698? U.S. Patent 7,651,698 has a statutory expiration date of November 29, 2023. However, patent term extensions or adjustments, as well as potential litigation outcomes, can affect the effective market exclusivity period. Can a company develop a JAK inhibitor that is structurally different but still infringes this patent? Yes, infringement is not solely based on identical structural replication. Doctrine of equivalents or broad interpretation of claim terms in litigation could lead to findings of infringement even for structurally similar compounds that perform a similar function through a similar means and achieve a similar result. What happens if a generic version of Xeljanz is launched before the patent expires or is successfully litigated? If a generic version is launched and the patent is still considered valid and infringed, the patent holder (typically the originator company) can sue for infringement. Remedies can include injunctions to remove the generic from the market and monetary damages. Are there any related patents to consider besides U.S. Patent 7,651,698 for tofacitinib? Yes, for a drug like tofacitinib, there are typically numerous related patents covering different aspects, including process patents for manufacturing, patents on specific polymorphs, formulation patents, and patents on new indications or combination therapies. A comprehensive analysis requires examining the full patent portfolio. Does the patent cover all JAK inhibitors, or only specific ones? U.S. Patent 7,651,698 covers a specific chemical class defined by a general formula and specific limitations. It does not cover all JAK inhibitors universally. However, its broad claims in the context of bicyclic heteroaryl compounds make it highly relevant to many compounds in this class, including tofacitinib. Citations [1] U.S. Patent 7,651,698 B2. (2010). Substituted bicyclic heteroaryl compounds. Retrieved from USPTO Patent Full-Text and Image Database. [2] Provisional U.S. Patent Application No. 60/429,661. (2002). [3] U.S. Patent Application No. 10/723,390. (2003). [4] International Patent Application No. WO 2004/048374 A1. (2004). [5] U.S. Food & Drug Administration. (n.d.). Approved drug products. Retrieved from FDA website. (Specific drug approval details for Xeljanz were consulted for general context of the associated drug). [6] Court documents and filings related to patent litigation involving tofacitinib and related patents. (General reference to publicly available legal databases and dockets). More… ↓ ⤷ Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 09811	Jul 23, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	373464	⤷ Start Trial
Austria	411003	⤷ Start Trial
Canada	2455633	⤷ Start Trial
China	101524337	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,651,698

Summary for Patent: 7,651,698